FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR How the Cancer Community Can Help Close the Care Gap This... February 4, 2022 Child Cancer Patient And His Dad Have A Little Fun When... October 3, 2019 Coronavirus reports – Part 8: “Going into hospital during this time... December 18, 2020 Best Friends and Owners of a Specialty Cheese Shop Battle Breast... June 11, 2021 Load more HOT NEWS Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... How to Support a Spouse or Partner During Cancer Treatment by... How Anxiety Impacts People With Cancer and How to Cope What to Know About Coping With Breast Cancer During Pregnancy: An...
